1405-37-4
Chemical Structure
Capreomycin sulfate
- CAS No.: 1405-37-4
- Formula:N/A
- Molecular Weight:N/A
IUPAC Name: 1-((Z)-((3S,9S,12S,15S)-15-amino-9-(aminomethyl)-12-(hydroxymethyl)-3-((R)-2-iminohexahydropyrimidin-4-yl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentaazacyclohexadecan-6-ylidene)methyl)urea sulfate
InChIKey: WLRKXTHNSQPQDY-WIBBCCSDSA-N
SMILES: OS(O)(=O)=O.[R]C[C@H](N1)C(N[C@@H](CNC(CC(N)CCCN)=O)C(N/C(C(N[C@H](C(NC[C@H](N)C1=O)=O)[C@@H]2NC(NCC2)=N)=O)=C\NC(N)=O)=O)=O.OS(O)(=O)=O.[R=OH 1A].[R=H 1B]
Biological Activity: Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Capreomycin sulfate | 99.0% | Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Maus CE, et al. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005 Feb;49(2):571-7. [Content Brief]
- [2]. Garcia-Contreras L, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007 Aug;51(8):2830-6. [Content Brief]
- [3]. Siddiqi M K, et al. Capreomycin inhibits the initiation of amyloid fibrillation and suppresses amyloid induced cell toxicity[J]. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2018, 1866(4): 549-557. [Content Brief]
- [4]. Reisfeld B, et al. A physiologically based pharmacokinetic model for capreomycin[J]. Antimicrobial agents and chemotherapy, 2012, 56(2): 926-934. [Content Brief]
- [5]. Le Conte P, et al. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model[J]. Antimicrobial agents and chemotherapy, 1994, 38(12): 2695-2701. [Content Brief]
